The Hygiology Post ® has been presenting information about a company formerly called Senesco Technologies which recently merged and rebranded to Sevion Therapeutics that seems to have much potential to help many people. As a matter of disclosure : The author continues to be a current shareholder in the company.
Earlier this month the article titled “Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO” (https://https://www.seviontherapeutics.com/wp-content/uploads/2015/06/83803181_2_Sevion-Press-Release-announcement-at-BIO-2015.pdf; obtained on 6-29-2015) began the following way:
“SAN DIEGO, CA – June 16, 2015 – Sevion Therapeutics, Inc. (‘Sevion’ or the ‘Company’) (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today provided an overview of the Company’s technology and programs by Dr. Miguel de los Rios, PhD, VP of Research and Development, at the BIO International Convention in Philadelphia, PA.
Technology Platform and Discovery Efforts. The Company has successfully completed an antibody discovery screening effort on both internal and partnered targets. The internal discovery program includes novel oncology GPCR targets. ‘To our knowledge we have the first antibodies against certain important GPCRs associated with several cancers,’ said Dr. de los Rios. The Company believes it has a position in the expanding field of immuno oncology, where several transmembrane proteins are currently not drugged due to discovery technology limitations. ‘Our proprietary platform for discovering antibodies against multipass membrane proteins provides a unique opportunity for us to target pathways in immuno oncology that regulate T-cell destruction of cancers. Additionally, our core capabilities are in immunology and oncology, so antibody discovery and development in this area will play to our strengths,’ noted Dr. de los Rios. Additionally, the Company has expanded and optimized production of its arrayed antibody library, which will enhance the efficiency by which it discovers leads for difficult transmembrane targets.
SVN-001 Development. The Company’s humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action, which has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2015 The Hygiology Post ®